Latest News and Press Releases

NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...

Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief...

NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...

NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...

Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programsCompany receives infusion of an additional $5 million from exercise of...

ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...

--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...

--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...

NEW YORK and CLEVELAND, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene...

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...